On November 14, China Securities Regulatory Commission (CSRC) released supplementary material requirements for overseas listings (November 10-14, 2025). The CSRC's international department disclosed additional documentation requests for 10 companies, including Changchun High-Tech Industry (Group) Co.,Ltd. (000661.SZ), which was asked to clarify its fundraising purposes and provide details about its AI large model-related business operations.
According to Hong Kong Exchange filings on September 29, Changchun High-Tech had submitted a main board listing application with CITIC Securities International as its sole sponsor. The CSRC requested Changchun High-Tech to supplement the following information, requiring legal verification and clear opinions:
1. Disclosure of ultimate beneficial ownership structure regarding its controlling shareholder Jilin Xinzheng Fund Partnership, including any prohibited investors under regulations. 2. Explanation of potential control changes due to share pledges by controlling shareholders before/after listing, assessing compliance with overseas listing rules. 3. Detailed disclosure of AI large model applications, including specific scenarios and functionalities. 4. Comprehensive breakdown of intended use of IPO proceeds. 5. Legal compliance opinions regarding corporate establishment and historical equity changes (currently only major aspects verified). 6. Additional requirements: - Enhanced legal opinions per overseas listing guidelines - Detailed disclosure of subsidiaries' businesses including internet services, clinical trials, medical research, and cell technology - covering actual operations, required licenses, involvement in restricted areas like stem cells/gene therapy, and foreign investment compliance.
According to its prospectus, Changchun High-Tech is an innovation-driven pharmaceutical group with products spanning therapeutic biologics, chemical drugs, vaccines, and traditional Chinese medicines. Frost & Sullivan data shows it's among few domestic companies with full-chain capabilities across these categories. The company has established diversified portfolios in endocrine/metabolic diseases, women's health, immunology/respiratory, oncology, vaccines and TCM sectors.